October 30, 2017
IfPA is concerned that ICER’s draft evidence report, dated October 2, 2017, undervalues the benefits that tardive dyskinesia (TD) patients…
October 11, 2017
Treating chronic low back pain with approaches such as yoga and talk therapy is cost effective, the Institute for Clinical and Economic Review announced this month. Will health plans respond by expanding coverage for non-pharmacologic therapies?
September 22, 2017
How do you put a price tag on a drug that offers life-altering results – but for a small group of patients? The question is becoming increasingly relevant with the rise of innovative, targeted medicine.
August 15, 2017
Innovation comes at a price, one that health insurers may hesitate to pay.
July 27, 2017
Nearly one in five Americans with hepatitis C spends time behind bars each year, making the prison system an opportune environment to test and cure potential transmitters of the disease.
July 25, 2017
Accessing innovative cardiovascular drugs may soon get harder.
July 6, 2017
Long-awaited treatment for a movement disorder known as tardive dyskinesia could remain out of reach – unless an upcoming cost-effectiveness analysis acknowledges its value to patients.
June 2, 2017
Abuse-deterrent formulations (ADF) of opioids resist crushing or dissolving for misuse, helping to curb widespread opioid abuse.
But a recent report from the Institute for Clinical and Economic Review underestimates ADFs’ value by ignoring several key benefits.
June 2, 2017
ICER’s report on opioid ADFs lays out several important facts. First, pain is a significant medical problem with potentially devastating…
May 9, 2017
“Doctor, make my pain go away.” I hear this plea, in one form or another, from patients on a daily basis. Yet it presents physicians like me with a troubling conundrum.
